|
|
|
51-200 employees
View all
|
|
biotechnology
|
|
New York, NY, US
|
|
Y-mAbs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express GD2 and B7-H3, respectively.
Our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. With the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
|
Y-mAbs Therapeutics, Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{last} | [email protected] |
75%
|
The widely used Y-mAbs Therapeutics, Inc. email format is {last} (e.g. [email protected]) with 75% adoption across the company.
To contact Y-mAbs Therapeutics, Inc. customer service number in your country click here to find.
Michael Rossi is the CEO of Y-mAbs Therapeutics, Inc.. To contact Michael Rossi email at [email protected] or [email protected]. Or you may call 2153214000
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.